Last reviewed · How we verify
TI-001
At a glance
| Generic name | TI-001 |
|---|---|
| Also known as | Intranasal oxytocin |
| Sponsor | Trigemina, Inc |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- TI-001 (Intranasal Oxytocin) for Treatment of High Frequency Episodic Migraine and Chronic Migraine (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TI-001 CI brief — competitive landscape report
- TI-001 updates RSS · CI watch RSS
- Trigemina, Inc portfolio CI